Trial Profile
A Real-world study on the safety and efficacy of daclatasvir+asunaprevir combination therapy for the treatment of chronic hepatitis C genotype 1b infection in patients with renal dysfunction
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 31 Jan 2017 New trial record